Treatment for adult ADHD using Jornay PM

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy and tolerability of Jornay PM, a sustained-release formulation of methylphenidate, in adults with Attention-deficit/Hyperactivity Disorder (ADHD). Participants will be randomized to receive the medication, which is uniquely taken in the evening to provide symptom relief throughout the following day. The study will gather important data on how this treatment affects ADHD symptoms, executive function, and emotional regulation in adults. This is the first clinical trial to assess the effects of Jornay PM specifically in the adult population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults ages 18-60 years, inclusive at the time of consent
2. Able to provide signed informed consent
3. Any gender
4. Subjects with a current primary Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 diagnosis of ADHD of predominantly inattentive presentation, or combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2.
5. Subjects who are not receiving any pharmacological treatment for ADHD must have an DSM AISRS 18 item total score of ≥ 28 at screening. Subjects who were previously receiving pharmacological treatment for ADHD at screening must have a minimum total DSM AISRS 18 item score of ≥ 22 at screening
6. Dysthymia and anxiety disorders in remission, but stable on psychiatric medication for three weeks or more at the discretion of principal investigator will be allowed. Medication for these disorders to remain constant for the duration of the protocol.
7. Subjects, who have not used stimulant medication in the past 2 months.
8. Occasional use of marijuana (less than 3 times weekly) will be allowed during screening process until subject is enrolled into the study. After subject is enrolled onto Jornay PM, subject is asked to complete an attestation. The attestation will state that the subject will not consume marijuana while in the study.
9. No illicit substance will be allowed at screening or during the study.

Exclusion Criteria:

1. Known hypersensitivity to methylphenidate, or product components.
2. Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.
3. Lifetime bipolar disorder, psychotic disorders, autism, intellectual disability except mood disorders accepted under the inclusion criteria at the discretion of the principal investigator.
4. Active suicidality within past year, or history of suicide attempt in past 2 years
5. Any history of severe past drug dependence determined by the Mini International Neuropsychiatric Interview (MINI) (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty)
6. Concurrent substance abuse and/or history of substance use within 6 months (except for marijuana use of less than three times a week and/or history of excessive marijuana use of less than three times a week within 6 months).
7. Use of any prescribed benzodiazepine
8. Any unstable medical or neurological condition; clinically significant medical abnormalities such as cardiovascular abnormalities, and any chronic condition of the central nervous system
9. Antidepressants and anti-anxiety agents (including benzodiazepines) taken in stable doses will be allowed, while other psychotropic medications, including hallucinogens, mood stabilizers, antipsychotics will not be allowed
10. Known nonresponse to MPH treatment
11. History of allergic reaction or sensitivity to MPH
12. Female of childbearing age, who are breastfeeding, pregnant, planning to be pregnant or men planning to make a woman pregnant during the study or for one-month post study
13. PI/clinician discretion

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Lenard Adler, MD — NYU Langone Health
• Study coordinator: Terry Leon, MS, RN
• Email: Terry.Leon@nyulangone.org
• Phone: 646-754-4841

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Augmenting Parent Management Training with a Smartphone Tool

  This study tests whether adding a smartphone app to parent management training helps reduce irritability and temper outbursts in kids aged 8–13 with disruptive behavior disorders.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07764536

• Centanafadine in adults with ADHD and emotional dysregulation

  This study tests centanafadine XR once daily to see if it helps adults with ADHD who also have emotional dysregulation.

  Recruiting at 16 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Gainesville, Florida and 15 other locations · NCT07759154

• Effect of raising a child with ADHD on mothers' fibromyalgia burden

  We will see if mothers aged 18–50 who have fibromyalgia and a child with ADHD have more disease burden than mothers with fibromyalgia whose children do not have psychiatric disorders.

  Recruiting Sultan 1. Murat State Hospital · Edirne · NCT07327775

• Tablet-based NDTx-02 program to improve executive function in children with ADHD or autism

  This pilot test tries a tablet-based digital therapeutic called NDTx-02 alongside usual care to see if it helps executive function in children aged 5–12 with ADHD or autism.

  Recruiting at 3 sites Neudive Inc. · Daegu and 2 other locations · NCT07242625

• Remote monitoring program for ADHD in rural children

  This study is testing a new remote monitoring program for children with ADHD in rural areas to see if it helps caregivers report symptoms better than just using standard educational materials.

  Recruiting at 2 sites IDeA States Pediatric Clinical Trials Network · Jackson, Mississippi and 1 other locations · NCT06743425

• Washing gut bacteria to treat ADHD

  This study is testing if a special treatment that cleans gut bacteria can help children with ADHD feel better and improve their symptoms.

  Recruiting at 2 sites The Second Hospital of Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT06376331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.